In Tuesday’s plenary session, investigators, including Joshua Baker, MD, MSCE, presented new data on a lifestyle intervention trial for rheumatoid arthritis, the first head-to-head trial looking at a primary joint endpoint in psoriatic arthritis, longitudinal risk stratification in pulmonary sarcoidosis, disease prediction models, infliximab biosimilar…
Jeong Min Yu, MD, MS, and other medical officers from the U.S. Food and Drug Administration discussed approvals including a Janus kinase and tyrosine kinase 2 inhibitor for dermatomyositis and an interleukin-23 antagonist for psoriatic arthritis, both for the treatment of adults.
Christine Stamatos, DNP, ANP-C, outlined a fibromyalgia “toolbox” designed for the implementation of evidence-based treatment approaches. “We have to educate patients and help them understand what they have control over,” she said.
S. Sam Lim, MD, MPH, and other experts will illustrate how rheumatology professionals can make the field more precise, more rigorous, and more equitable by recognizing the intertwined relationship between social and structural context and disease management.
Sarah B. Lieber, MD, MS, will moderate a session focused on how three individuals and their care teams have personalized the management of their rheumatic disease to the patients’ benefit. The presenters will explain how their experiences have been leveraged to create resources and strategies…
Stephanie Faubion, MD, MBA, and Karen Costenbader, MD, MPH, reviewed new evidence about the value of hormone therapy for patients with autoimmune disease in menopause and post menopause.
Miriah Gillispie-Taylor, MD, summarized 21 papers spanning five themes: providing feedback, teaching and assessing clinical skills, rethinking fellowship, extending the reach of rheumatology, and emerging approaches to instruction.
Speakers, including Arinola Dada, MD, FACR, outlined strategies for launching and sustaining clinical trials. They discussed how to gain experience to be ready to be a site leader, what it means to work with a site management organization, and more.
In Monday’s plenary session, investigators, including Walter P. Maksymowych, MD, FRCPC, MRCP, FACP, presented new data on gout flares and cardiovascular events, molecular heterogeneity in preclinical lupus, giant cell arteritis disease trajectory, obinutuzumab use in lupus, how methotrexate is metabolized, and what makes an MRI…
The prize recognizes seminal discoveries that shift the understanding of lupus. Greg Barton, PhD, and Olivia Majer, PhD, will discuss their research into how regulation of innate immune-sensing pathways governs susceptibility to lupus.